APO Research
Talk to an analyst

APO RESEARCH · REPORT

Aprepitant

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Aprepitant Market Outlook and Growth Opportunities 2026

22 December 2025192 pages

Choose your research edition.

Industry ResearchAprepitant Industry Research Report 2026117 pages · $2,950 USDIndustry Growth & TrendsGlobal Aprepitant Industry Growth and Trends Forecast to 203298 pages · $3,450 USDMarket StructureGlobal Aprepitant Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032188 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Aprepitant Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Aprepitant Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Aprepitant market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Aprepitant is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Aprepitant is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Aprepitant is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Aprepitant market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Aprepitant market include Shanghai Yingrui Biomedical Technology Co., Ltd., Sandoz, Merck & Co., Vea Impex (I) Pvt. Ltd., Heron Therapeutics, Glenmark Pharmaceuticals, Aetos Pharma, Actiza Pharmaceutical and Aark Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Aprepitant market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Aprepitant and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Aprepitant sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Aprepitant market size, projected growth trends, production technologies, key applications, and end-use industries.

Aprepitant Segment by Company

Shanghai Yingrui Biomedical Technology Co., Ltd.

Sandoz

Merck & Co.

Vea Impex (I) Pvt. Ltd.

Heron Therapeutics

Glenmark Pharmaceuticals

Aetos Pharma

Actiza Pharmaceutical

Aark Pharmaceuticals

Aprepitant Segment by Type

Injection

Oral

Aprepitant Segment by Application

Hospital

Drug store

Aprepitant Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Aprepitant status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Aprepitant market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Aprepitant significant trends, drivers, influence factors in global and regions.

6. To analyze Aprepitant competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Aprepitant market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Aprepitant and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Aprepitant.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Aprepitant market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Aprepitant industry.

Chapter 3: Detailed analysis of Aprepitant manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Aprepitant in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Aprepitant in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Aprepitant Industry Trends Table 2. Aprepitant Industry Drivers Table 3. Aprepitant Industry Opportunities and Challenges Table 4. Aprepitant Industry Restraints Table 5. Global Aprepitant Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Aprepitant Revenue Share by Company (2021-2026) Table 7. Global Aprepitant Sales Volume by Company (k units) & (2021-2026) Table 8. Global Aprepitant Sales Volume Share by Company (2021-2026) Table 9. Global Aprepitant Average Price (US$/unit) of Company (2021-2026) Table 10. Global Aprepitant Company Ranking, (2024-2026) & (USD Million) Table 11. Global Aprepitant Key Company Manufacturing Base & Headquarters Table 12. Global Aprepitant Company, Product Type & Application Table 13. Global Aprepitant Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Aprepitant by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Injection Table 18. Significant Companies of Oral Table 19. Global Aprepitant Sales Volume by Type 2021 VS 2025 VS 2032 (k units) Table 20. Global Aprepitant Sales Volume by Type (2021-2026) & (k units) Table 21. Global Aprepitant Sales Volume by Type (2027-2032) & (k units) Table 22. Global Aprepitant Sales Volume Share by Type (2021-2026) Table 23. Global Aprepitant Sales Volume Share by Type (2027-2032) Table 24. Global Aprepitant Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Aprepitant Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Aprepitant Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Aprepitant Sales Value Share by Type (2021-2026) Table 28. Global Aprepitant Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Hospital Table 30. Significant Companies of Drug store Table 31. Global Aprepitant Sales Volume by Application 2021 VS 2025 VS 2032 (k units) Table 32. Global Aprepitant Sales Volume by Application (2021-2026) & (k units) Table 33. Global Aprepitant Sales Volume by Application (2027-2032) & (k units) Table 34. Global Aprepitant Sales Volume Share by Application (2021-2026) Table 35. Global Aprepitant Sales Volume Share by Application (2027-2032) Table 36. Global Aprepitant Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Aprepitant Sales Value by Application (2021-2026) & (US$ Million) Table 38. Global Aprepitant Sales Value by Application (2027-2032) & (US$ Million) Table 39. Global Aprepitant Sales Value Share by Application (2021-2026) Table 40. Global Aprepitant Sales Value Share by Application (2027-2032) Table 41. Global Aprepitant Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 42. Global Aprepitant Sales by Region (2021-2026) & (k units) Table 43. Global Aprepitant Sales Market Share by Region (2021-2026) Table 44. Global Aprepitant Sales by Region (2027-2032) & (k units) Table 45. Global Aprepitant Sales Market Share by Region (2027-2032) Table 46. Global Aprepitant Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 47. Global Aprepitant Sales Value by Region (2021-2026) & (US$ Million) Table 48. Global Aprepitant Sales Value Share by Region (2021-2026) Table 49. Global Aprepitant Sales Value by Region (2027-2032) & (US$ Million) Table 50. Global Aprepitant Sales Value Share by Region (2027-2032) Table 51. Global Aprepitant Market Average Price (US$/unit) by Region (2021-2026) Table 52. Global Aprepitant Market Average Price (US$/unit) by Region (2027-2032) Table 53. Global Aprepitant Sales by Country: 2021 VS 2025 VS 2032 (k units) Table 54. Global Aprepitant Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 55. Global Aprepitant Sales by Country (2021-2026) & (k units) Table 56. Global Aprepitant Sales Market Share by Country (2021-2026) Table 57. Global Aprepitant Sales by Country (2027-2032) & (k units) Table 58. Global Aprepitant Sales Market Share by Country (2027-2032) Table 59. Global Aprepitant Sales Value by Country (2021-2026) & (US$ Million) Table 60. Global Aprepitant Sales Value Market Share by Country (2021-2026) Table 61. Global Aprepitant Sales Value by Country (2027-2032) & (US$ Million) Table 62. Global Aprepitant Sales Value Market Share by Country (2027-2032) Table 63. Shanghai Yingrui Biomedical Technology Co., Ltd. Company Information Table 64. Shanghai Yingrui Biomedical Technology Co., Ltd. Business Overview Table 65. Shanghai Yingrui Biomedical Technology Co., Ltd. Aprepitant Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 66. Shanghai Yingrui Biomedical Technology Co., Ltd. Aprepitant Product Portfolio Table 67. Shanghai Yingrui Biomedical Technology Co., Ltd. Recent Development Table 68. Sandoz Company Information Table 69. Sandoz Business Overview Table 70. Sandoz Aprepitant Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 71. Sandoz Aprepitant Product Portfolio Table 72. Sandoz Recent Development Table 73. Merck & Co. Company Information Table 74. Merck & Co. Business Overview Table 75. Merck & Co. Aprepitant Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 76. Merck & Co. Aprepitant Product Portfolio Table 77. Merck & Co. Recent Development Table 78. Vea Impex (I) Pvt. Ltd. Company Information Table 79. Vea Impex (I) Pvt. Ltd. Business Overview Table 80. Vea Impex (I) Pvt. Ltd. Aprepitant Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 81. Vea Impex (I) Pvt. Ltd. Aprepitant Product Portfolio Table 82. Vea Impex (I) Pvt. Ltd. Recent Development Table 83. Heron Therapeutics Company Information Table 84. Heron Therapeutics Business Overview Table 85. Heron Therapeutics Aprepitant Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 86. Heron Therapeutics Aprepitant Product Portfolio Table 87. Heron Therapeutics Recent Development Table 88. Glenmark Pharmaceuticals Company Information Table 89. Glenmark Pharmaceuticals Business Overview Table 90. Glenmark Pharmaceuticals Aprepitant Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 91. Glenmark Pharmaceuticals Aprepitant Product Portfolio Table 92. Glenmark Pharmaceuticals Recent Development Table 93. Aetos Pharma Company Information Table 94. Aetos Pharma Business Overview Table 95. Aetos Pharma Aprepitant Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 96. Aetos Pharma Aprepitant Product Portfolio Table 97. Aetos Pharma Recent Development Table 98. Actiza Pharmaceutical Company Information Table 99. Actiza Pharmaceutical Business Overview Table 100. Actiza Pharmaceutical Aprepitant Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 101. Actiza Pharmaceutical Aprepitant Product Portfolio Table 102. Actiza Pharmaceutical Recent Development Table 103. Aark Pharmaceuticals Company Information Table 104. Aark Pharmaceuticals Business Overview Table 105. Aark Pharmaceuticals Aprepitant Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 106. Aark Pharmaceuticals Aprepitant Product Portfolio Table 107. Aark Pharmaceuticals Recent Development Table 108. Key Raw Materials Table 109. Raw Materials Key Suppliers Table 110. Aprepitant Distributors List Table 111. Aprepitant Customers List Table 112. Research Programs/Design for This Report Table 113. Authors List of This Report Table 114. Secondary Sources Table 115. Primary Sources List of Figures Figure 1. Aprepitant Product Image Figure 2. Global Aprepitant Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Aprepitant Sales Value (2021-2032) & (US$ Million) Figure 4. Global Aprepitant Sales (2021-2032) & (k units) Figure 5. Global Aprepitant Sales Average Price (US$/unit) & (2021-2032) Figure 6. Global Aprepitant Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Injection Image Figure 10. Oral Image Figure 11. Global Aprepitant Sales Volume by Type (2021 VS 2025 VS 2032) & (k units) Figure 12. Global Aprepitant Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Aprepitant Sales Volume Share by Type (2021-2032) Figure 14. Global Aprepitant Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Aprepitant Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Aprepitant Sales Value Share by Type (2021-2032) Figure 17. Hospital Image Figure 18. Drug store Image Figure 19. Global Aprepitant Sales Volume by Application (2021 VS 2025 VS 2032) & (k units) Figure 20. Global Aprepitant Sales Volume Share 2021 VS 2025 VS 2032 Figure 21. Global Aprepitant Sales Volume Share by Application (2021-2032) Figure 22. Global Aprepitant Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Aprepitant Sales Value Share 2021 VS 2025 VS 2032 Figure 24. Global Aprepitant Sales Value Share by Application (2021-2032) Figure 25. Global Aprepitant Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 26. Global Aprepitant Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 27. Global Aprepitant Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 28. Global Aprepitant Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 29. North America Aprepitant Sales Value (2021-2032) & (US$ Million) Figure 30. North America Aprepitant Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Europe Aprepitant Sales Value (2021-2032) & (US$ Million) Figure 32. Europe Aprepitant Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Asia-Pacific Aprepitant Sales Value (2021-2032) & (US$ Million) Figure 34. Asia-Pacific Aprepitant Sales Value Share by Country (%), 2025 VS 2032 Figure 35. South America Aprepitant Sales Value (2021-2032) & (US$ Million) Figure 36. South America Aprepitant Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Middle East & Africa Aprepitant Sales Value (2021-2032) & (US$ Million) Figure 38. Middle East & Africa Aprepitant Sales Value Share by Country (%), 2025 VS 2032 Figure 39. USA Aprepitant Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. USA Aprepitant Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. USA Aprepitant Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Canada Aprepitant Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Canada Aprepitant Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Canada Aprepitant Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Mexico Aprepitant Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Mexico Aprepitant Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Mexico Aprepitant Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Germany Aprepitant Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Germany Aprepitant Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Germany Aprepitant Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. France Aprepitant Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. France Aprepitant Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. France Aprepitant Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. U.K. Aprepitant Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. U.K. Aprepitant Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. U.K. Aprepitant Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Italy Aprepitant Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Italy Aprepitant Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Italy Aprepitant Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Spain Aprepitant Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Spain Aprepitant Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Spain Aprepitant Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Russia Aprepitant Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Russia Aprepitant Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Russia Aprepitant Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Netherlands Aprepitant Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Netherlands Aprepitant Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Netherlands Aprepitant Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Nordic Countries Aprepitant Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Nordic Countries Aprepitant Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Nordic Countries Aprepitant Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. China Aprepitant Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. China Aprepitant Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. China Aprepitant Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Japan Aprepitant Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Japan Aprepitant Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Japan Aprepitant Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. South Korea Aprepitant Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. South Korea Aprepitant Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. South Korea Aprepitant Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. India Aprepitant Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. India Aprepitant Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. India Aprepitant Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Australia Aprepitant Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Australia Aprepitant Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Australia Aprepitant Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Southeast Asia Aprepitant Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Southeast Asia Aprepitant Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Southeast Asia Aprepitant Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Brazil Aprepitant Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Brazil Aprepitant Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Brazil Aprepitant Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Argentina Aprepitant Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Argentina Aprepitant Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Argentina Aprepitant Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Chile Aprepitant Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Chile Aprepitant Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Chile Aprepitant Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Colombia Aprepitant Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Colombia Aprepitant Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Colombia Aprepitant Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Peru Aprepitant Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Peru Aprepitant Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Peru Aprepitant Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Saudi Arabia Aprepitant Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Saudi Arabia Aprepitant Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Aprepitant Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Israel Aprepitant Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Israel Arabia Aprepitant Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Israel Arabia Aprepitant Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. UAE Aprepitant Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. UAE Aprepitant Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. UAE Aprepitant Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Turkey Aprepitant Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Turkey Aprepitant Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Turkey Aprepitant Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Iran Aprepitant Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Iran Aprepitant Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Iran Aprepitant Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Egypt Aprepitant Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Egypt Aprepitant Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Egypt Aprepitant Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Aprepitant Value Chain Figure 124. Manufacturing Cost Structure Figure 125. Aprepitant Sales Mode & Process Figure 126. Direct Comparison with Distribution Share Figure 127. Distributors Profiles Figure 128. Years Considered Figure 129. Research Process Figure 130. Key Executives Interviewed

Scope & coverage.

Types
  • Injection
  • Oral
Applications
  • Hospital
  • Drug store
Companies covered
  • Shanghai Yingrui Biomedical Technology Co., Ltd.
  • Sandoz
  • Merck & Co.
  • Vea Impex (I) Pvt. Ltd.
  • Heron Therapeutics
  • Glenmark Pharmaceuticals
  • Aetos Pharma
  • Actiza Pharmaceutical
  • Aark Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Aprepitant Sales Value (2021-2032)
  4. 1.2.2 Global Aprepitant Sales Volume (2021-2032)
  5. 1.2.3 Global Aprepitant Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Aprepitant Market Dynamics
  1. 2.1 Aprepitant Industry Trends
  2. 2.2 Aprepitant Industry Drivers
  3. 2.3 Aprepitant Industry Opportunities and Challenges
  4. 2.4 Aprepitant Industry Restraints
3 Aprepitant Market by Company
  1. 3.1 Global Aprepitant Company Revenue Ranking in 2025
  2. 3.2 Global Aprepitant Revenue by Company (2021-2026)
  3. 3.3 Global Aprepitant Sales Volume by Company (2021-2026)
  4. 3.4 Global Aprepitant Average Price by Company (2021-2026)
  5. 3.5 Global Aprepitant Company Ranking (2024-2026)
  6. 3.6 Global Aprepitant Company Manufacturing Base and Headquarters
  7. 3.7 Global Aprepitant Company Product Type and Application
  8. 3.8 Global Aprepitant Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Aprepitant Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Aprepitant Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Aprepitant Market by Type
  1. 4.1 Aprepitant Type Introduction
  2. 4.1.1 Injection
  3. 4.1.2 Oral
  4. 4.2 Global Aprepitant Sales Volume by Type
  5. 4.2.1 Global Aprepitant Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Aprepitant Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Aprepitant Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Aprepitant Sales Value by Type
  9. 4.3.1 Global Aprepitant Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Aprepitant Sales Value by Type (2021-2032)
  11. 4.3.3 Global Aprepitant Sales Value Share by Type (2021-2032)
5 Aprepitant Market by Application
  1. 5.1 Aprepitant Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Drug store
  4. 5.2 Global Aprepitant Sales Volume by Application
  5. 5.2.1 Global Aprepitant Sales Volume by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Aprepitant Sales Volume by Application (2021-2032)
  7. 5.2.3 Global Aprepitant Sales Volume Share by Application (2021-2032)
  8. 5.3 Global Aprepitant Sales Value by Application
  9. 5.3.1 Global Aprepitant Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Aprepitant Sales Value by Application (2021-2032)
  11. 5.3.3 Global Aprepitant Sales Value Share by Application (2021-2032)
6 Aprepitant Regional Sales and Value Analysis
  1. 6.1 Global Aprepitant Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Aprepitant Sales by Region (2021-2032)
  3. 6.2.1 Global Aprepitant Sales by Region: 2021-2026
  4. 6.2.2 Global Aprepitant Sales by Region (2027-2032)
  5. 6.3 Global Aprepitant Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Aprepitant Sales Value by Region (2021-2032)
  7. 6.4.1 Global Aprepitant Sales Value by Region: 2021-2026
  8. 6.4.2 Global Aprepitant Sales Value by Region (2027-2032)
  9. 6.5 Global Aprepitant Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Aprepitant Sales Value (2021-2032)
  12. 6.6.2 North America Aprepitant Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Aprepitant Sales Value (2021-2032)
  15. 6.7.2 Europe Aprepitant Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Aprepitant Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Aprepitant Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Aprepitant Sales Value (2021-2032)
  21. 6.9.2 South America Aprepitant Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Aprepitant Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Aprepitant Sales Value Share by Country, 2025 VS 2032
7 Aprepitant Country-level Sales and Value Analysis
  1. 7.1 Global Aprepitant Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Aprepitant Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Aprepitant Sales by Country (2021-2032)
  4. 7.3.1 Global Aprepitant Sales by Country (2021-2026)
  5. 7.3.2 Global Aprepitant Sales by Country (2027-2032)
  6. 7.4 Global Aprepitant Sales Value by Country (2021-2032)
  7. 7.4.1 Global Aprepitant Sales Value by Country (2021-2026)
  8. 7.4.2 Global Aprepitant Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Aprepitant Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Aprepitant Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Aprepitant Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Aprepitant Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Aprepitant Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Aprepitant Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Aprepitant Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Aprepitant Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Aprepitant Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Aprepitant Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Aprepitant Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Aprepitant Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Aprepitant Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Aprepitant Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Aprepitant Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Aprepitant Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Aprepitant Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Aprepitant Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Aprepitant Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Aprepitant Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Aprepitant Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Aprepitant Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Aprepitant Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Aprepitant Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Aprepitant Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Aprepitant Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Aprepitant Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Aprepitant Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Aprepitant Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Aprepitant Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Aprepitant Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Aprepitant Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Aprepitant Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Aprepitant Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Aprepitant Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Aprepitant Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Aprepitant Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Aprepitant Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Aprepitant Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Aprepitant Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Aprepitant Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Aprepitant Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Aprepitant Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Aprepitant Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Aprepitant Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Aprepitant Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Aprepitant Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Aprepitant Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Aprepitant Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Aprepitant Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Aprepitant Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Aprepitant Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Aprepitant Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Aprepitant Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Aprepitant Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Aprepitant Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Aprepitant Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Aprepitant Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Aprepitant Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Aprepitant Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Aprepitant Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Aprepitant Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Aprepitant Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Aprepitant Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Aprepitant Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Aprepitant Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Aprepitant Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Aprepitant Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Aprepitant Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Aprepitant Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Aprepitant Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Aprepitant Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Aprepitant Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Aprepitant Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Aprepitant Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Aprepitant Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Aprepitant Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Aprepitant Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Aprepitant Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Aprepitant Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Aprepitant Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Aprepitant Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Aprepitant Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Aprepitant Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Shanghai Yingrui Biomedical Technology Co., Ltd.
  2. 8.1.1 Shanghai Yingrui Biomedical Technology Co., Ltd. Company Information
  3. 8.1.2 Shanghai Yingrui Biomedical Technology Co., Ltd. Business Overview
  4. 8.1.3 Shanghai Yingrui Biomedical Technology Co., Ltd. Aprepitant Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Shanghai Yingrui Biomedical Technology Co., Ltd. Aprepitant Product Portfolio
  6. 8.1.5 Shanghai Yingrui Biomedical Technology Co., Ltd. Recent Developments
  7. 8.2 Sandoz
  8. 8.2.1 Sandoz Company Information
  9. 8.2.2 Sandoz Business Overview
  10. 8.2.3 Sandoz Aprepitant Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Sandoz Aprepitant Product Portfolio
  12. 8.2.5 Sandoz Recent Developments
  13. 8.3 Merck & Co.
  14. 8.3.1 Merck & Co. Company Information
  15. 8.3.2 Merck & Co. Business Overview
  16. 8.3.3 Merck & Co. Aprepitant Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Merck & Co. Aprepitant Product Portfolio
  18. 8.3.5 Merck & Co. Recent Developments
  19. 8.4 Vea Impex (I) Pvt. Ltd.
  20. 8.4.1 Vea Impex (I) Pvt. Ltd. Company Information
  21. 8.4.2 Vea Impex (I) Pvt. Ltd. Business Overview
  22. 8.4.3 Vea Impex (I) Pvt. Ltd. Aprepitant Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Vea Impex (I) Pvt. Ltd. Aprepitant Product Portfolio
  24. 8.4.5 Vea Impex (I) Pvt. Ltd. Recent Developments
  25. 8.5 Heron Therapeutics
  26. 8.5.1 Heron Therapeutics Company Information
  27. 8.5.2 Heron Therapeutics Business Overview
  28. 8.5.3 Heron Therapeutics Aprepitant Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Heron Therapeutics Aprepitant Product Portfolio
  30. 8.5.5 Heron Therapeutics Recent Developments
  31. 8.6 Glenmark Pharmaceuticals
  32. 8.6.1 Glenmark Pharmaceuticals Company Information
  33. 8.6.2 Glenmark Pharmaceuticals Business Overview
  34. 8.6.3 Glenmark Pharmaceuticals Aprepitant Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Glenmark Pharmaceuticals Aprepitant Product Portfolio
  36. 8.6.5 Glenmark Pharmaceuticals Recent Developments
  37. 8.7 Aetos Pharma
  38. 8.7.1 Aetos Pharma Company Information
  39. 8.7.2 Aetos Pharma Business Overview
  40. 8.7.3 Aetos Pharma Aprepitant Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Aetos Pharma Aprepitant Product Portfolio
  42. 8.7.5 Aetos Pharma Recent Developments
  43. 8.8 Actiza Pharmaceutical
  44. 8.8.1 Actiza Pharmaceutical Company Information
  45. 8.8.2 Actiza Pharmaceutical Business Overview
  46. 8.8.3 Actiza Pharmaceutical Aprepitant Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Actiza Pharmaceutical Aprepitant Product Portfolio
  48. 8.8.5 Actiza Pharmaceutical Recent Developments
  49. 8.9 Aark Pharmaceuticals
  50. 8.9.1 Aark Pharmaceuticals Company Information
  51. 8.9.2 Aark Pharmaceuticals Business Overview
  52. 8.9.3 Aark Pharmaceuticals Aprepitant Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Aark Pharmaceuticals Aprepitant Product Portfolio
  54. 8.9.5 Aark Pharmaceuticals Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Aprepitant Value Chain Analysis
  2. 9.1.1 Aprepitant Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Aprepitant Sales Mode & Process
  6. 9.2 Aprepitant Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Aprepitant Distributors
  9. 9.2.3 Aprepitant Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst